Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax Plus Azacitidine in MDS-IB2
NCT07885397Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax in myelodysplastic syndrome (MDS), sponsored by Shanghai General Hospital. Started Oct 2026; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07885397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885397.